Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

Bristol Myers Squibb announces positive trial results for treatment of MS

Bristol Myers Squibb announces positive trial results for treatment of MS

Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment Bristol Myers Squibb has revealed two-year results from the POETYK PSO trial involving its psoriasis therapy, deucravacitinib. ... Jonathan Sadeh, senior vice president of immunology and fibrosis development at Bristol Myers Squibb, said: “Our

BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program

BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program The Bristol Myers Squibb Foundation (BMSF), the National Medical Fellowships (NMF) and the American Association for Cancer Research (AACR) have revealed a new name for its initiative to increase clinical trial ... Commenting on Winn’s contributions,

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma Bristol Myers Squibb (BMS) has announced that Opdualag (nivolumab and relatlimab-rmbw) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult and paediatric patients

FDA approves BMS’ Opdivo with chemotherapy for certain lung cancer patients

FDA approves BMS’ Opdivo with chemotherapy for certain lung cancer patients Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for use in combination with chemotherapy every three weeks for three cycles.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
The digital-first launch: the key to connected stakeholder experiences?
During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...